ACE2 provided significant renal protection in patients with diabetes, while ACE2 deficiency aggravated diabetic kidney injury, rhACE2 has therapeutic effects in experimental Alport syndrome and diabetic nephropathy.[44,45] The results of Marfella et al[46] showed that high glucose environment was more conducive to the formation of glycosylated ACE2, and the expression of glycosylated ACE2 in cardiomyocytes was strongly correlated with blood glucose control. This evidence concerns the gene ACE2 and Alport syndrome.